Cargando…

SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique

INTRODUCTION: In Sofala province (Mozambique), young people living with HIV (YPLHIV) are estimated at 7% among people aged 15–24 years. Even though the COVID-19 pandemic threatened HIV health services, data on the impact of COVID-19 on YPLHIV people are lacking. This study aimed at exploring the ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Benoni, Roberto, Casigliani, Virginia, Zin, Annachiara, Giannini, Dara, Ronzoni, Niccolò, Di Chiara, Costanza, Chhaganlal, Kajal, Donà, Daniele, Merolle, Ada, Dos Anjos, Helga Guambe, Chenene, Fernando, Tognon, Francesca, Putoto, Giovanni, Giaquinto, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656907/
https://www.ncbi.nlm.nih.gov/pubmed/37978353
http://dx.doi.org/10.1186/s12879-023-08808-6
_version_ 1785148096815038464
author Benoni, Roberto
Casigliani, Virginia
Zin, Annachiara
Giannini, Dara
Ronzoni, Niccolò
Di Chiara, Costanza
Chhaganlal, Kajal
Donà, Daniele
Merolle, Ada
Dos Anjos, Helga Guambe
Chenene, Fernando
Tognon, Francesca
Putoto, Giovanni
Giaquinto, Carlo
author_facet Benoni, Roberto
Casigliani, Virginia
Zin, Annachiara
Giannini, Dara
Ronzoni, Niccolò
Di Chiara, Costanza
Chhaganlal, Kajal
Donà, Daniele
Merolle, Ada
Dos Anjos, Helga Guambe
Chenene, Fernando
Tognon, Francesca
Putoto, Giovanni
Giaquinto, Carlo
author_sort Benoni, Roberto
collection PubMed
description INTRODUCTION: In Sofala province (Mozambique), young people living with HIV (YPLHIV) are estimated at 7% among people aged 15–24 years. Even though the COVID-19 pandemic threatened HIV health services, data on the impact of COVID-19 on YPLHIV people are lacking. This study aimed at exploring the seroprevalence of SARS-CoV-2 and associated factors among young people based on their HIV status. METHODS: A cross-sectional study was conducted, including people aged 18–24 attending a visit at one of the adolescent-friendly health services in Sofala province between October and November 2022. People vaccinated against SARS-COV-2 or YPLHIV with WHO stage III-IV were excluded. A SARS-CoV-2 antibodies qualitative test and a questionnaire investigating socio-demographic and clinical characteristics were proposed. SARS-CoV-2 seroprevalence was calculated with Clopper-Pearson method. The odds ratio (OR) of a positive SARS-CoV-2 antibodies test was estimated through multivariable binomial logistic regression. RESULTS: In total, 540 young people including 65.8% women and 16.7% YPLHIV participated in the survey.. The mean age was 20.2 years (SD 2.0). Almost all the sample (96.1%) reported adopting at least one preventive measure for COVID-19. The weighted seroprevalence of SARS-CoV-2 in the whole sample was 46.8% (95%CI 42.6–51.2) and 35.9% (95%CI 25.3–47.5) in YPLHIV. The adjusted OR of testing positive at the SARS-CoV-2 antibodies test was higher in students compared to workers (aOR:2.02[0.95CI 1.01–4.21]) and in those with symptoms (aOR:1.52[0.95CI 1.01–2.30]). There were no differences based on HIV status(aOR:0.663[95%CI 0.406–1.069]). Overall, COVID-19 symptoms were reported by 68 (28.2%) people with a positive serological SARS-CoV-2 test and by 7 (21.7%) YPLHIV (p = 0.527). No one required hospitalization. CONCLUSIONS: SARS-CoV-2 seroprevalence was 46.8% without differences in risk of infection or clinical presentation based on HIV status. This result may be influenced by the exclusion of YPLHIV with advanced disease. The higher risk among students suggests the schools’ role in spreading the virus. It’s important to continue monitoring the impact of COVID-19 on YPLHIV to better understand its effect on screening and adherence to treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08808-6.
format Online
Article
Text
id pubmed-10656907
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106569072023-11-17 SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique Benoni, Roberto Casigliani, Virginia Zin, Annachiara Giannini, Dara Ronzoni, Niccolò Di Chiara, Costanza Chhaganlal, Kajal Donà, Daniele Merolle, Ada Dos Anjos, Helga Guambe Chenene, Fernando Tognon, Francesca Putoto, Giovanni Giaquinto, Carlo BMC Infect Dis Research INTRODUCTION: In Sofala province (Mozambique), young people living with HIV (YPLHIV) are estimated at 7% among people aged 15–24 years. Even though the COVID-19 pandemic threatened HIV health services, data on the impact of COVID-19 on YPLHIV people are lacking. This study aimed at exploring the seroprevalence of SARS-CoV-2 and associated factors among young people based on their HIV status. METHODS: A cross-sectional study was conducted, including people aged 18–24 attending a visit at one of the adolescent-friendly health services in Sofala province between October and November 2022. People vaccinated against SARS-COV-2 or YPLHIV with WHO stage III-IV were excluded. A SARS-CoV-2 antibodies qualitative test and a questionnaire investigating socio-demographic and clinical characteristics were proposed. SARS-CoV-2 seroprevalence was calculated with Clopper-Pearson method. The odds ratio (OR) of a positive SARS-CoV-2 antibodies test was estimated through multivariable binomial logistic regression. RESULTS: In total, 540 young people including 65.8% women and 16.7% YPLHIV participated in the survey.. The mean age was 20.2 years (SD 2.0). Almost all the sample (96.1%) reported adopting at least one preventive measure for COVID-19. The weighted seroprevalence of SARS-CoV-2 in the whole sample was 46.8% (95%CI 42.6–51.2) and 35.9% (95%CI 25.3–47.5) in YPLHIV. The adjusted OR of testing positive at the SARS-CoV-2 antibodies test was higher in students compared to workers (aOR:2.02[0.95CI 1.01–4.21]) and in those with symptoms (aOR:1.52[0.95CI 1.01–2.30]). There were no differences based on HIV status(aOR:0.663[95%CI 0.406–1.069]). Overall, COVID-19 symptoms were reported by 68 (28.2%) people with a positive serological SARS-CoV-2 test and by 7 (21.7%) YPLHIV (p = 0.527). No one required hospitalization. CONCLUSIONS: SARS-CoV-2 seroprevalence was 46.8% without differences in risk of infection or clinical presentation based on HIV status. This result may be influenced by the exclusion of YPLHIV with advanced disease. The higher risk among students suggests the schools’ role in spreading the virus. It’s important to continue monitoring the impact of COVID-19 on YPLHIV to better understand its effect on screening and adherence to treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08808-6. BioMed Central 2023-11-17 /pmc/articles/PMC10656907/ /pubmed/37978353 http://dx.doi.org/10.1186/s12879-023-08808-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Benoni, Roberto
Casigliani, Virginia
Zin, Annachiara
Giannini, Dara
Ronzoni, Niccolò
Di Chiara, Costanza
Chhaganlal, Kajal
Donà, Daniele
Merolle, Ada
Dos Anjos, Helga Guambe
Chenene, Fernando
Tognon, Francesca
Putoto, Giovanni
Giaquinto, Carlo
SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique
title SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique
title_full SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique
title_fullStr SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique
title_full_unstemmed SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique
title_short SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique
title_sort sars-cov-2 seroprevalence and associated factors, based on hiv serostatus, in young people in sofala province, mozambique
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656907/
https://www.ncbi.nlm.nih.gov/pubmed/37978353
http://dx.doi.org/10.1186/s12879-023-08808-6
work_keys_str_mv AT benoniroberto sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT casiglianivirginia sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT zinannachiara sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT gianninidara sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT ronzoniniccolo sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT dichiaracostanza sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT chhaganlalkajal sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT donadaniele sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT merolleada sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT dosanjoshelgaguambe sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT chenenefernando sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT tognonfrancesca sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT putotogiovanni sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique
AT giaquintocarlo sarscov2seroprevalenceandassociatedfactorsbasedonhivserostatusinyoungpeopleinsofalaprovincemozambique